Floatz logo

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)

T Acute Lymphoblastic Leukemia

University of Washingtonprotein_peptidePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
73/ 100

Competitive context

79 Active assets in the T Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
Daunorubicin
SWOG Cancer Research Network
Phase 3BB
PEGASPARGASE
Children's Oncology Group
Phase 3BB
PREDNISONE TABLETS
Children's Oncology Group
Phase 3BB

View all 50 →

Same molecule, other indications

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:

Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
L1 Childhood Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →